Chemicals · Founded 1954 · www.naperolinvestments.com · BSE 500298 · NSE NAPEROL · ISIN INE585A01020
No Notes Added Yet
Business
Naperol Investments Ltd., identifiable by its ticker NATPEROXID, operates in the Chemicals sector, specifically within the Chemicals industry in India. While its name suggests an investment focus, the ticker "NATPEROXID" strongly indicates a primary operational business in the manufacturing and distribution of peroxygen chemicals, most likely hydrogen peroxide and its derivatives. The company's core business model would involve producing these chemicals in large scale and supplying them to various industrial end-users. It makes money by selling its chemical products, capitalizing on manufacturing efficiency and market demand for these essential industrial intermediates.
Revenue Mix
Specific segment breakdowns are not publicly available. However, based on the nature of peroxygen chemicals like hydrogen peroxide, the company's revenue would likely be generated from sales to diverse industrial sectors. These typically include:
Pulp & Paper: For bleaching applications.
Textiles: For bleaching and desizing.
Water Treatment: As an oxidant for purification and disinfection.
Chemical Synthesis: As an oxidizing agent in various chemical processes.
Food Processing: For sterilization and sanitization.
Healthcare & Cosmetics: For disinfectants and personal care products.
While the "Investments" part of its name suggests potential other revenue streams, the primary operational focus is inferred to be chemicals.
Industry
The Indian chemicals industry, particularly for bulk commodities like hydrogen peroxide, is characterized by its capital-intensive nature and the importance of economies of scale. It often features a few large players due to high entry barriers (technology, capital, regulatory approvals). Naperol Investments Ltd. would be positioned as a participant in the Indian peroxygen chemicals market. Success in this segment often depends on cost leadership, consistent product quality, and reliable supply chain management. The company would compete against other domestic producers and potentially imports, vying for market share in various end-use applications.
MOAT
For a bulk chemical producer like Naperol Investments Ltd., sustainable competitive advantages, or "moats," are often derived from:
Scale and Cost Leadership: Large-scale operations can lead to lower per-unit production costs, offering a pricing advantage.
Process Technology: Proprietary or highly efficient manufacturing processes can reduce operational expenses.
Integrated Operations: Vertical integration (e.g., in raw materials) can provide cost stability and supply assurance.
Customer Relationships & Distribution: Established relationships and a robust distribution network ensure steady demand and efficient delivery.
Switching Costs: While hydrogen peroxide is a commodity, for certain industrial clients, switching suppliers might involve qualifying new products or adjusting processes, creating minor switching costs.
Without specific details, the company's moat would primarily rely on its operational efficiency, scale, and ability to manage costs effectively in a commodity market.
Growth Drivers
Key factors that could drive Naperol Investments Ltd.'s growth over the next 3-5 years include:
Industrial Growth in India: Overall economic and industrial expansion in India will drive demand across all end-use sectors (pulp & paper, textiles, chemicals, water treatment).
Increased Environmental Regulations: Growing emphasis on cleaner production processes and water treatment will boost demand for hydrogen peroxide as a greener oxidant and bleaching agent.
Hygiene and Healthcare Demands: Rising health consciousness and demand for disinfectants and sanitizers will support growth.
Capacity Expansion: Any strategic investments in expanding production capacity to meet growing demand.
New Applications: Development of new applications for peroxygen chemicals in emerging industries.
Risks
Commodity Price Volatility: Fluctuations in raw material prices (e.g., natural gas, electricity, petrochemicals) and finished product prices can impact profitability significantly.
Intense Competition: The commodity nature of peroxygen chemicals can lead to pricing pressure and margin erosion from domestic and international competitors.
Regulatory & Environmental Changes: Strict environmental regulations or changes in safety standards could require significant capital expenditure or impact operational flexibility.
Technological Obsolescence: While hydrogen peroxide production is mature, new, more efficient, or cheaper production methods could emerge.
Economic Downturns: Recessions or slowdowns in key end-user industries would directly impact demand for the company's products.
Currency Fluctuations: For import of raw materials or export of finished goods, unfavorable exchange rate movements can affect costs and revenues.
Management & Ownership
In India, companies like Naperol Investments Ltd. are often promoter-led. Without specific information, it is assumed that the promoters (founding families or major shareholders) play a significant role in strategic decision-making. The quality of management would be assessed by their ability to navigate commodity cycles, ensure operational efficiency, manage capital allocation (especially given the "Investments" aspect), and steer the company through regulatory and competitive landscapes. Ownership structure would likely involve a significant promoter holding, alongside institutional and public shareholders.
Outlook
Naperol Investments Ltd. operates in a crucial segment of the Indian chemical industry, benefiting from the country's industrialization and increasing focus on environmental sustainability. The demand for peroxygen chemicals like hydrogen peroxide is expected to grow steadily across various sectors, presenting a favorable backdrop. However, the company faces inherent challenges associated with a commodity business, including volatile raw material costs, intense competition, and pricing pressures. Its ability to maintain cost leadership through operational excellence, strategically expand capacity, and potentially diversify into higher-margin specialty grades will be critical. The "Investments" aspect of the name introduces an additional layer, and its impact on core chemical operations and overall strategy would need closer examination to fully understand the company's trajectory.
| #(Fig in Cr.) | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 64 | 29 | 68 | 80 | 50 | 76 | 97 | 115 | 88 | 80 |
| Other Income | 4 | 3 | 4 | 1 | 2 | 2 | 3 | 3 | 1 | 1 |
| Total Income | 68 | 32 | 72 | 81 | 52 | 77 | 100 | 119 | 90 | 81 |
| Total Expenditure | 58 | 40 | 55 | 62 | 52 | 72 | 90 | 88 | 70 | 70 |
| Operating Profit | 9 | -8 | 17 | 19 | -0 | 6 | 10 | 30 | 20 | 11 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 5 | 5 |
| Exceptional Income / Expenses | -13 | 0 | 0 | 0 | 7 | 16 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -11 | -15 | 10 | 12 | 0 | 15 | 4 | 23 | 14 | 6 |
| Provision for Tax | -2 | -4 | 3 | 3 | 0 | 4 | 1 | 6 | 4 | 1 |
| Profit After Tax | -8 | -11 | 7 | 9 | -0 | 11 | 3 | 17 | 11 | 4 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | -8 | -11 | 7 | 9 | -0 | 11 | 3 | 17 | 11 | 4 |
| Adjusted Earnings Per Share | -14.6 | -18.5 | 12.7 | 15.4 | -0.1 | 19.8 | 5.4 | 30.3 | 18.5 | 7.5 |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 155 | 213 | 236 | 197 | 234 | 233 | 306 | 402 | 191 | 215 | 226 | 380 |
| Other Income | 2 | 5 | 6 | 6 | 8 | 6 | 10 | 19 | 18 | 13 | 10 | 8 |
| Total Income | 157 | 218 | 242 | 203 | 242 | 239 | 316 | 421 | 209 | 228 | 236 | 390 |
| Total Expenditure | 107 | 146 | 174 | 174 | 198 | 163 | 161 | 175 | 166 | 170 | 209 | 318 |
| Operating Profit | 50 | 72 | 68 | 29 | 44 | 77 | 156 | 246 | 44 | 58 | 27 | 71 |
| Interest | 0 | 0 | 0 | 5 | 5 | 2 | 1 | 1 | 3 | 13 | 9 | 5 |
| Depreciation | 10 | 11 | 10 | 7 | 9 | 9 | 9 | 9 | 11 | 17 | 17 | 21 |
| Exceptional Income / Expenses | 0 | 0 | 1 | 0 | -1 | -8 | 1 | 0 | 0 | -15 | 7 | 0 |
| Profit Before Tax | 39 | 61 | 60 | 17 | 29 | 58 | 147 | 236 | 30 | 12 | 8 | 47 |
| Provision for Tax | 11 | 21 | 20 | 10 | 11 | 19 | 51 | 82 | 12 | -9 | 3 | 12 |
| Profit After Tax | 28 | 40 | 40 | 7 | 18 | 39 | 96 | 154 | 18 | 21 | 5 | 35 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 28 | 40 | 40 | 7 | 18 | 39 | 96 | 154 | 18 | 21 | 5 | 35 |
| Adjusted Earnings Per Share | 48.5 | 69.7 | 69.5 | 11.6 | 32.1 | 67.2 | 166.8 | 267.6 | 31.2 | 36.8 | 9.4 | 61.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | -17% | -1% | 4% |
| Operating Profit CAGR | -53% | -52% | -19% | -6% |
| PAT CAGR | -76% | -68% | -34% | -16% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -43% | -18% | -24% | -6% |
| ROE Average | 1% | 2% | 6% | 10% |
| ROCE Average | 2% | 2% | 9% | 16% |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 150 | 180 | 210 | 212 | 224 | 742 | 1017 | 1174 | 802 | 1067 | 911 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 30 | 10 | 0 | 0 | 70 | 0 | 0 | 14 |
| Other Non-Current Liabilities | 72 | 18 | 19 | 108 | 117 | 27 | 37 | 40 | 216 | 216 | 215 |
| Total Current Liabilities | 36 | 41 | 62 | 76 | 49 | 38 | 39 | 59 | 217 | 160 | 108 |
| Total Liabilities | 258 | 238 | 291 | 426 | 400 | 807 | 1093 | 1342 | 1235 | 1442 | 1247 |
| Fixed Assets | 118 | 110 | 117 | 187 | 180 | 178 | 170 | 166 | 372 | 342 | 338 |
| Other Non-Current Assets | 64 | 15 | 59 | 96 | 99 | 500 | 713 | 844 | 673 | 936 | 785 |
| Total Current Assets | 76 | 113 | 115 | 143 | 121 | 129 | 210 | 333 | 189 | 165 | 125 |
| Total Assets | 258 | 238 | 291 | 426 | 400 | 807 | 1093 | 1342 | 1235 | 1442 | 1247 |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 11 | 2 | 7 |
| Cash Flow from Operating Activities | 47 | 42 | 29 | 21 | 22 | 60 | 95 | 148 | 16 | 61 | 9 |
| Cash Flow from Investing Activities | -35 | -30 | -22 | -75 | 30 | -33 | -56 | -175 | -39 | -7 | 34 |
| Cash Flow from Financing Activities | -12 | -13 | -7 | 54 | -51 | -28 | -35 | 35 | 14 | -49 | -49 |
| Net Cash Inflow / Outflow | 0 | -1 | 0 | 1 | 0 | -1 | 3 | 8 | -9 | 5 | -6 |
| Closing Cash & Cash Equivalent | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 11 | 2 | 7 | 1 |
| # | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 48.48 | 69.71 | 69.5 | 11.62 | 32.1 | 67.23 | 166.76 | 267.61 | 31.17 | 36.85 | 9.45 |
| CEPS(Rs) | 65.91 | 88.85 | 86.44 | 24.17 | 47.69 | 82.76 | 182.75 | 283.68 | 50.71 | 67.3 | 39.79 |
| DPS(Rs) | 12 | 15 | 15 | 5 | 10 | 34 | 65 | 65 | 12.5 | 12.5 | 5 |
| Book NAV/Share(Rs) | 260.6 | 312.87 | 364.82 | 369.69 | 389.76 | 1290.39 | 1769.37 | 2042.43 | 1395.69 | 1856.21 | 1584.48 |
| Core EBITDA Margin(%) | 28 | 28.26 | 23.74 | 10.15 | 13.92 | 26.86 | 46.2 | 56.4 | 13.37 | 20.08 | 7.29 |
| EBIT Margin(%) | 23.36 | 25.65 | 22.85 | 9.82 | 13.25 | 22.88 | 46.84 | 58.85 | 16.89 | 11.09 | 7.2 |
| Pre Tax Margin(%) | 23.12 | 25.5 | 22.76 | 7.68 | 11.19 | 22.04 | 46.68 | 58.67 | 15.46 | 5.47 | 3.41 |
| PAT Margin (%) | 16.41 | 16.83 | 15.23 | 3.04 | 7.07 | 14.73 | 30.44 | 38.23 | 9.37 | 9.42 | 2.33 |
| Cash Profit Margin (%) | 22.31 | 21.45 | 18.94 | 6.33 | 10.5 | 18.13 | 33.36 | 40.53 | 15.24 | 17.2 | 9.81 |
| ROA(%) | 12.5 | 16.16 | 15.1 | 1.86 | 4.47 | 6.4 | 10.09 | 12.63 | 1.39 | 1.58 | 0.4 |
| ROE(%) | 19.92 | 24.31 | 20.51 | 3.16 | 8.45 | 8 | 10.9 | 14.04 | 1.81 | 2.27 | 0.55 |
| ROCE(%) | 27.01 | 36.35 | 30.38 | 8.63 | 12.81 | 11.92 | 16.67 | 20.86 | 2.91 | 2.32 | 1.53 |
| Receivable days | 55.28 | 42.96 | 44.64 | 57.97 | 48.83 | 45.79 | 50.09 | 38.04 | 59.97 | 45.52 | 33.44 |
| Inventory Days | 32.79 | 14.68 | 22.38 | 33.27 | 21.06 | 17.54 | 14.97 | 21.11 | 53.64 | 33.56 | 36.16 |
| Payable days | 204.2 | 156.95 | 130.96 | 117.7 | 98.58 | 112.43 | 87.7 | 93.18 | 94.69 | 91.17 | 56.53 |
| PER(x) | 8.33 | 6.41 | 6.19 | 48.34 | 17.28 | 14.58 | 14.01 | 10.53 | 37.64 | 59.53 | 167.99 |
| Price/Book(x) | 1.55 | 1.43 | 1.18 | 1.52 | 1.42 | 0.76 | 1.32 | 1.38 | 0.84 | 1.18 | 1 |
| Dividend Yield(%) | 2.97 | 3.35 | 3.48 | 0.89 | 1.8 | 3.47 | 2.78 | 2.31 | 1.07 | 0.57 | 0.32 |
| EV/Net Sales(x) | 1.52 | 1.21 | 1.06 | 2 | 1.49 | 2.46 | 4.37 | 4.19 | 4.35 | 6.41 | 4.45 |
| EV/Core EBITDA(x) | 4.74 | 3.56 | 3.65 | 13.72 | 7.82 | 7.49 | 8.61 | 6.84 | 19.13 | 23.78 | 36.9 |
| Net Sales Growth(%) | -15.19 | 37.66 | 10.79 | -16.58 | 18.93 | -0.39 | 31.41 | 31.33 | -52.46 | 12.43 | 5.08 |
| EBIT Growth(%) | -53.69 | 53.88 | -1.83 | -64.06 | 60.53 | 73.62 | 145.66 | 60.53 | -86.36 | -22.75 | -32.73 |
| PAT Growth(%) | -51.05 | 43.8 | -0.3 | -83.29 | 176.38 | 109.42 | 148.06 | 60.48 | -88.35 | 18.2 | -74.36 |
| EPS Growth(%) | -51.05 | 43.8 | -0.3 | -83.29 | 176.38 | 109.42 | 148.06 | 60.48 | -88.35 | 18.2 | -74.36 |
| Debt/Equity(x) | 0.04 | 0.01 | 0.02 | 0.34 | 0.14 | 0.01 | 0 | 0.07 | 0.2 | 0.12 | 0.1 |
| Current Ratio(x) | 2.1 | 2.78 | 1.84 | 1.88 | 2.47 | 3.36 | 5.32 | 5.69 | 0.87 | 1.03 | 1.15 |
| Quick Ratio(x) | 1.79 | 2.58 | 1.46 | 1.67 | 2.18 | 3.07 | 4.95 | 5.28 | 0.76 | 0.92 | 0.88 |
| Interest Cover(x) | 97.36 | 175.83 | 276.84 | 4.6 | 6.42 | 27.16 | 291.52 | 323.92 | 11.8 | 1.97 | 1.9 |
| Total Debt/Mcap(x) | 0.02 | 0 | 0.02 | 0.23 | 0.1 | 0.02 | 0 | 0.05 | 0.24 | 0.1 | 0.1 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 |
| FII | 0 | 0.67 | 1.91 | 1.98 | 1.98 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| Public | 29.23 | 28.56 | 27.32 | 27.25 | 27.25 | 27.47 | 27.47 | 27.47 | 27.48 | 27.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| FII | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.17 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +5% | -17% | -1% | +4% |
| Operating Profit CAGR | -53% | -52% | -19% | -6% |
| PAT CAGR | -76% | -68% | -34% | -16% |
| Share Price CAGR | -43% | -18% | -24% | -6% |
| ROE Average | +1% | +2% | +6% | +10% |
| ROCE Average | +2% | +2% | +9% | +16% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 | 70.76 |
| FII | 0 | 0.67 | 1.91 | 1.98 | 1.98 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| Public | 29.23 | 28.56 | 27.32 | 27.25 | 27.25 | 27.47 | 27.47 | 27.47 | 27.48 | 27.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| FII | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.17 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.